A number of factors may contribute to the failure of this strategy, including lack of IGF-1R expression in endocrine-resistant breast cancer and induction of hyperglycemia and hyperinsulinemia caused by IGF-1R mAbs2–4. This evidence concerns the gene IGF1R and Hyperglycemia.